Medical Research & News

Through a collaborative approach to research support, the Foundation is focused on improving diagnosis, treatment therapies, better understanding of the disease burden, and advocating for increased research funding that can benefit patients --- with an ultimate goal of helping researchers find a cure for cutaneous lymphoma.

Research

Lymphoma Scientific Research Mentoring Program Partnership
The Cutaneous Lymphoma Foundation is honored to be in partnership with the Lymphoma Research Foundation to offer the Leet Family Cutaneous Lymphoma Cutaneous Lymphoma Scholar as a special research initiative in the 2027-2029 Lymphoma Scientific Research Mentoring Program (LSRMP).
Research

Quality of Life Workshop
What does quality of life really mean for people living with cutaneous lymphoma? In November 2026, the Cutaneous Lymphoma Foundation will bring together multi-stakeholders for a first-of-its-kind workshop focused on turning insights into action and improving daily life for the cutaneous lymphoma community.
Research

ONO-4685 Clinical Trial
ONO-4685 is an investigational anti-PD-1/CD3 bispecific antibody, which binds specifically to human PD-1 and CD3 being developed as a potential treatment of both autoimmune diseases and hematologic malignancies. The clinical study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Research

Collaboration to Advance T Cell Lymphoma Research
The Cutaneous Lymphoma Foundation sponsors cutaneous lymphoma track at the Lymphoma Research Foundation's T-cell Lymphomas International Scientific Workshop. The purpose of the workshop is to help expand the understanding of T-cell lymphomas.

Targeted Therapy: PTX-100
PTX-100 is a targeted therapy. It is a first in class compound with the ability to block an important cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. PTX-100 is now in a Phase 2 clinical trial in T cell lymphomas, where it is showing encouraging efficacy and safety.

LYMPHIR™ (denileukin diftitox-cxdl)
LYMPHIR is a targeted immune therapy indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

HyBryte™ (FLASH)
FLASH (Fluorescent Light Activated Synthetic Hypericin) is a potential new treatment for early stage cutaneous lymphoma using visible fluorescent light pursuing a New Drug Application (NDA) filing in the United States

TELLOMAK Study
A study evaluating the efficacy and safety of a monoclonal antibody called lauctamab - alone or in combination with chemotherapy - in patients with advanced T-cell lymphoma.
Research

EORTC-CLG Annual Scientific Meeting Highlights
October 2021 - Highlights from the 2021 EORTC-CLG Scientific Meeting clinical presentations
Patient Resources

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR®
April 2020 - Helsinn Therapeutics (U.S.), Inc., the US subsidiary of the Swiss pharmaceutical group focused on building quality cancer care products, today announces a change to the financial assistance program for VALCHLOR® (mechlorethamine) gel 0.016% to ensure that commercially insured patients have access to treatment during the COVID-19 crisis.

American Society of Hematology Announces 2020 Scholar Award Recipients
December 2019 - The American Society of Hematology (ASH) announced the 39 recipients of its 2020 Scholar Awards. One of ASH’s most prestigious research award programs, the ASH Scholar Awards financially support fellows to junior faculty dedicated to careers in hematology research as they transition from training programs to careers as independent investigators. Awardees included cutaneous lymphoma researcher, Anjali Mishra, PhD. 
Research

FDA Approves Mogamulizumab for CTCL
The FDA has approved mogamulizumab-kpkc (Poteligeo) for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy.
Research

Research in Cutaneous Lymphoma: A Broad View
Since the development of the “scientific method,” people have been engaged in research in efforts to answer questions, solve problems, and add to our overall knowledge. Nowhere is this more evident than in the medical field, and in the study of cutaneous lymphoma.
Research

Protein Can Help Identify Which Rashes Are Early Mycosis Fungoides
Chronic rash in a sun-protected area that doesn’t respond to topical treatment likely needs to be evaluated for mycosis fungoides, the most common variant of cutaneous T-cell lymphoma. Now, a new VA study reports that a protein expression can help make the diagnosis.